Frontlight ResearchEarly access
Active, not recruitingNo phase
ALTERRA Post-Approval Study
Key facts
- Who runs it
- Edwards Lifesciences
- Where
- Aurora, Birmingham, Boston, Cincinnati, Columbus, Dallas, Durham, Gainesville, Houston, Little Rock, Los Angeles, Memphis, New York, Oak Lawn, Pittsburgh, Salt Lake City, San Diego, Seattle, St Louis, Stanford, and Tampa, United StatesSee the 23 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Active, not recruiting
- People taking part
- 150 people enrolled
- Started
- 12 May 2022
- Expected to end
- Jul 2035
- Type of study
- Observational
- Treatments tested
- Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System
- Record updated
- 5 October 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Native or surgically-repaired RVOT with severe PR
- Clinically indicated for pulmonary valve replacement
- Planned for treatment with the Alterra prestent and SAPIEN 3 THV
Who cannot take part
- Active bacterial endocarditis or other active infections
- Inability to tolerate an anticoagulation/antiplatelet regimen
Where in United States
Also in 1 other country, 1 site
- Colorado Children's HospitalAurora, United States
- Children's of AlabamaBirmingham, United States
- Boston Children's HospitalBoston, United States
- Cincinnati Children's HospitalCincinnati, United States
- Nationwide Children's HospitalColumbus, United States
- Medical City DallasDallas, United States
- Duke UniversityDurham, United States
- UF Health Shands HospitalGainesville, United States
- Children's Memorial Hermann HospitalHouston, United States
- Texas Children's HospitalHouston, United States
- Arkansas Children's HospitalLittle Rock, United States
- Cedars-Sinai Medical CenterLos Angeles, United States
- Le Bonheur Children's HospitalMemphis, United States
- Columbia UniversityNew York, United States
- Icahn School of Medicine at Mount SinaiNew York, United States
- Advocate Children's HospitalOak Lawn, United States
- UPMC Children's Hospital of PittsburghPittsburgh, United States
- Primary Children's HospitalSalt Lake City, United States
- Rady Children's HospitalSan Diego, United States
- Seattle Children's HospitalSeattle, United States
- Washington University in St. LouisSt Louis, United States
- Stanford UniversityStanford, United States
- St. Joseph's Children's HospitalTampa, United States
About the trial
What the trial wants to find out
This study will monitor device performance and outcomes in subjects undergoing implantation of the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent in the post-approval setting
The group in the trial
- TPVR
Transcatheter Pulmonary Valve Replacement
Treatment: Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Multicenter Post-Approval Study of Congenital Pulmonic Valve Dysfunction Studying the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System With Alterra Adaptive Prestent
- Record updated
- 5 October 2026